Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.50 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.46 |
| ▸ | BCR | P11274 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181460 | 0.78 | TDP1 (0.53) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL209239 | 0.78 | HSD17B10 (0.50) | MEN1KMT2AALDH1A1TDP1ERN1 | |
| SCHEMBL4891988 | 0.77 | ESR1 (0.54) | ESR1ESR2ABL1ABCB1BCR | |
| SCHEMBL4891993 | 0.77 | ESR1 (0.54) | ESR1ESR2ABL1ABCB1BCR | |
| SCHEMBL4897425 | 0.77 | ESR1 (0.50) | ESR1ESR2ERN1 | |
| SCHEMBL10539436 | 0.76 | AHR (0.65) | ESR1ESR2ABL1ABCB1BCR | |
| SCHEMBL14399886 | 0.76 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1TDP1ERN1 | |
| SCHEMBL6335821 | 0.72 | AHR (0.70) | ESR1ESR2ABL1ABCB1BCR | |
| SCHEMBL28923728 | 0.71 | SENP1 (0.45) | ESR1ESR2ERN1ALDH5A1ABAT | |
| SCHEMBL6702064 | 0.71 | ALDH5A1 (0.50) | ESR1ESR2ALDH1A1ERN1ALDH5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620392-B1 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-06-27 | — | — | EP | claimed |
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-7279600-B2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1808429-A2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | Wyeth a Corporation of the State of Delaware (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1620392-B1 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1620392-A2 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050020676-A1 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH | 2005-01-27 | — | — | US | disclosed |
| WO-2004099122-A2 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | ESR1, ESR2, ESRRB | ESR1 1/4885ESR2 2/4885ABL1 171/4885 |
| US-20050020676-A1 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, ESRRB | ESR1 1/4885ESR2 2/4885ABL1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.